Recurrence of major depressive disorder across different treatment settings: Results from the NESDA study

Hardeveld, Florian; Spijker, Jan; Graaf, Ron de; Hendriks, Sanne M.; Licht, Carmilla M.M.; Nolen, Willem A.; Penninx, Brenda W. J. H.; Beekman, Aartjan T.F.

doi:10.1016/j.jad.2012.11.008

Cited by 80 publications

(74 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…34 In the Netherlands, a 2-year follow-up of 375 patients with MDD in remission for 3 months found recurrence in 26.8% of patients treated in primary care and 33.5% in specialized mental health care. 35 …”

Section: What Is the Risk Of Relapse Or Recurrence?mentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

et al. 2016

View full text Add to dashboard Cite

Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals. Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. This section is the first of six guidelines articles.Results: In Canada, the annual and lifetime prevalence of MDD was 4.7% and 11.3%, respectively. MDD represents the second leading cause of global disability, with high occupational and economic impact mainly attributable to indirect costs. DSM-5 criteria for depressive disorders remain relatively unchanged, but other clinical dimensions (sleep, cognition, physical symptoms) may have implications for depression management. e-Mental health is increasingly used to support clinical and selfmanagement of MDD. In the 2-phase (acute and maintenance) treatment model, specific goals address symptom remission, functional recovery, improved quality of life, and prevention of recurrence. Conclusions:The burden attributed to MDD remains high, whether from individual distress, functional and relationship impairment, reduced quality of life, or societal economic cost. Applying core principles of care, including comprehensive assessment, therapeutic alliance, support of self-management, evidence-informed treatment, and measurement-based care, will optimize clinical, quality of life, and functional outcomes in MDD.

show abstract

Section: What Is the Risk Of Relapse Or Recurrence?mentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

et al. 2016

View full text Add to dashboard Cite

show abstract

“…En la literatura internacional, la historia de depresión se ha asociado con una mayor recurrencia del cuadro 25 , observándose que la patología tiene un desarrollo crónico en un tercio de los pacientes deprimidos del nivel primario [26][27][28] , incrementando el riesgo de padecer un peor estado de salud y discapacidad funcional por períodos prolongados 25,29 .…”

Section: Discussionunclassified

Comorbilidad en personas con depresión que consultan en centros de la atención primaria de salud en Santiago, Chile

et al. 2017

View full text Add to dashboard Cite

“…Exclusion criteria at baseline included (1) a primary clinical other psychiatric diagnosis, such as a psychotic disorder, obsessive-compulsive disorder, bipolar disorder or severe addiction disorder, and (2) lack of fluency in Dutch. Diagnosis of depression and alcohol dependence or abuse was based on the Composite International Diagnostic Interview (CIDI), which establishes diagnoses according to DSM-IV criteria [32]. Depression severity was determined using the 30-item Inventory of Depressive Symptoms Self-Report Questionnaire (IDS-SR30; depression severity classification is calculated by summing the scores: none = 0-13, mild = 14-25, moderate = 26-38, severe = 39-48, very severe = 49-84) [33].…”

Section: Methodsmentioning

confidence: 99%

Identification of an Immune-Neuroendocrine Biomarker Panel for Detection of Depression: A Joint Effects Statistical Approach

Chan

Cooper²,

Bot³

et al. 2015

Neuroendocrinology

Self Cite

View full text Add to dashboard Cite

Background/Aims: Less than half of depression patients are correctly diagnosed within the primary care setting. Previous proteomic studies have identified numerous immune and neuroendocrine changes in patients. However, few studies have considered the joint effects of biological molecules and their diagnostic potential. Our aim was to develop and validate a diagnostic serum biomarker panel identified through joint effects analysis of multiplex immunoassay profiling data from 1,007 clinical samples. Methods: In stage 1, we conducted a meta-analysis of two independent cohorts of 78 first-/recent-onset drug-naive/drug-free depression patients and 156 controls and applied the 10-fold cross-validation with least absolute shrinkage and selection operator regression to identify an optimal diagnostic prediction model (biomarker panel). In stage 2, we tested the discriminatory performance of this biomarker panel using the naturalistic Netherlands Study of Depression and Anxiety (NESDA) cohort of 468 depression patients and 305 controls. Results: An optimal panel of 33 immune-neuroendocrine biomarkers and gender was selected in the meta-analysis. Testing this biomarker-gender panel using the NESDA cohort resulted in a moderate to good performance to differentiate patients from controls (0.69 < AUC < 0.86), particularly the first-episode patients free of chronic non-psychiatric diseases or medications and following incorporation of sociodemographic covariates (0.76 < AUC < 0.92). Conclusion: Despite the need for additional validation studies, we demonstrated that a blood-based biomarker-sociodemographic panel can detect depression in naturalistic healthcare settings with good discriminatory power. Further refinements of blood biomarker panels aiding in the diagnosis of depression may provide a cost-effective means to increase accuracy of clinical diagnosis within the primary care setting.

show abstract

Recurrence of major depressive disorder across different treatment settings: Results from the NESDA study

Abstract: Health care professionals in both settings should be aware of the same risk factors since the recurrence risk and its predictors appeared to be similar across settings.

Cited by 80 publications

References 37 publications

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

Comorbilidad en personas con depresión que consultan en centros de la atención primaria de salud en Santiago, Chile

Identification of an Immune-Neuroendocrine Biomarker Panel for Detection of Depression: A Joint Effects Statistical Approach

Contact Info

Product

Resources

About